Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 63% of modeled bridge. Strengths: Occupancy Rate. Risks: Bed Count, Commercial Payer %. Risk-adjusted uplift: $45.1M (vs $71.5M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $27.2M | $27.2M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $26.2M | $748K | $26.9M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $4.2M | $12.4M | $16.5M | $52.1M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $870K | $870K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 31.4% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $6.8M | $13.6M | $20.4M | $27.2M | $27.2M | $27.2M | $27.2M |
| Denial Rate Reduction | $0 | $6.7M | $13.5M | $20.2M | $26.9M | $26.9M | $26.9M | $26.9M |
| A/R Days Reduction | $0 | $5.5M | $11.0M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M |
| Clean Claim Rate | $0 | $435K | $870K | $870K | $870K | $870K | $870K | $870K |
| Cumulative | $0 | $19.5M | $39.0M | $58.0M | $71.5M | $71.5M | $71.5M | $71.5M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $71.5M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | -100% / 0.0x | Loss | Loss | Loss | Loss |
| 9.0x | -100% / 0.0x | -100% / 0.0x | Loss | Loss | Loss |
| 10.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 11.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
| 12.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x | -100% / 0.0x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 0% before the 6.5x covenant trips. RCM uplift reduces leverage from 99.0x to 99.0x, adding 0.0 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $-96.1M | — | $-96.1M | -7.1% |
| Year 1 | $-99.0M | +$47.7M | $-51.3M | -3.8% |
| Year 2 | $-102.0M | +$71.5M | $-30.5M | -2.2% |
| Year 3 | $-105.0M | +$71.5M | $-33.5M | -2.5% |
| Year 4 | $-108.2M | +$71.5M | $-36.7M | -2.7% |
| Year 5 | $-111.4M | +$71.5M | $-39.9M | -2.9% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $13.6M | $20.4M | $27.2M | $32.6M |
| Denial Rate Reductio | $13.5M | $20.2M | $26.9M | $32.3M |
| A/R Days Reduction | $8.3M | $12.4M | $16.5M | $19.9M |
| Clean Claim Rate | $435K | $653K | $870K | $1.0M |
| Total | $35.8M | $53.6M | $71.5M | $85.8M |
Peer Context — Where This Hospital Sits
Key metrics vs 13 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | -7.1% | -5.5% | -4.3% | -0.8% | P15 |
| Net-to-Gross | 31.1% | 26.9% | 30.4% | 31.4% | P62 |
| Occupancy | 66.4% | 76.3% | 80.2% | 88.8% | P8 |
| Rev/Bed | $1.5M | $1.6M | $1.9M | $2.7M | P15 |
| Exp/Bed | $1.6M | $1.6M | $2.1M | $2.9M | P15 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.